RxDoctor Payments Data

Charles Shapiro

Medical Oncology · New York, NYNPI 1972511103

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (51.2%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 3 manufacturers reported payments, led by Gilead at 52.2% of the total. Reporting peaked in 2022 at $1,190 and has fallen 96.0% since, to $48 in 2025. That places this record below the midpoint for medical oncology clinicians in NY, where the typical reported total is $4,912.

$1,250in general payments, 2019–2025

Across 6 payments — averaging $208.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$652
  • Daiichi Sankyo Inc.$550
  • Lilly USA, LLC$48
$903,449in research payments, 2019–2025

Across 24 payments — averaging $37,644 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Daiichi Sankyo Inc.$891K
  • Genentech, Inc.$12K

What the payments were for

  • Consulting fees$64051%
  • Speaking & faculty fees$55044%
  • Food & beverage$484%
  • Education$121%

General payments by program year

21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead3$652
Daiichi Sankyo Inc.1$550
Lilly USA, LLC2$48

How this compares

$1,250 in reported general payments places this provider in the 35th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York →

Other medical oncology in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →